Diamyd Medical AB (publ) and JDRF have entered into a fouour-year research and development collaboration including a non-dilutive $5 million award to Diamyd Medical to support its ongoing Phase 3 trial with the precision medicine antigen-specific immunotherapy Diamyd. The grant will be funded under JDRF's Industry Discovery & Development Partnerships program that focuses on commercialization of therapeutics and devices for the treatment, cure, and prevention of type 1 diabetes and its complications.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
13.9 SEK | +3.58% |
|
+1.16% | +111.57% |
08:15am | Diamyd Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2024 | CI |
16/05 | Diamyd Medical AB Updates on the Registrational Phase 3 Trial | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+111.57% | 13Cr | |
+16.45% | 12TCr | |
+21.96% | 12TCr | |
+24.08% | 2.7TCr | |
-20.05% | 2.04TCr | |
-17.31% | 1.64TCr | |
-16.28% | 1.59TCr | |
-44.35% | 1.56TCr | |
+63.91% | 1.49TCr | |
+2.52% | 1.36TCr |
- Stock Market
- Equities
- DMYD B Stock
- News Diamyd Medical AB
- Diamyd Medical AB Partners with JDRF to Advance the DIAGNODE-3 Phase 3 Trial in Type 1 Diabetes